Palvella's QTORIN™ Rapamycin Hits Primary Endpoint in Phase 3 Trial for Rare Lymphatic Malformations
Event summary
- Palvella's QTORIN™ rapamycin met primary endpoint in Phase 3 SELVA trial for microcystic lymphatic malformations, showing statistically significant improvement (p<0.001) on mLM-IGA.
- 86% of participants aged ≥ 6 were rated 'Much Improved' or 'Very Much Improved' at Week 24.
- Palvella plans to submit a New Drug Application to FDA in H2 2026, with potential approval in H1 2027.
- QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events reported.
The big picture
Palvella's positive Phase 3 results position QTORIN™ rapamycin as a potential first-in-class treatment for microcystic lymphatic malformations, a rare disease with no approved therapies. The success validates the company's mTOR pathway-targeting platform and sets the stage for regulatory approval, addressing a significant unmet need in rare skin diseases.
What we're watching
- Regulatory Pathway
- Whether the FDA will expedite review given Breakthrough Therapy and Orphan Drug designations.
- Market Potential
- The pace at which Palvella can capture the estimated 30,000 U.S. patients with microcystic LMs.
- Pipeline Expansion
- How success with QTORIN™ rapamycin will impact development of other QTORIN™-based therapies.
Related topics